BioCancell Therapeutics is dedicated to developing cancer treatments suitable for over 30 types of cancer, including ovarian cancer, bladder cancer and pancreatic cancer. BioCancell's patented, personalized cancer therapy approach is based on the identification of target oncogenes, such as H19. It aims to provide alternative cancer treatments that offer strong therapeutic efficacy combined with a lack of side effects.

The first cancer treatment utilizing H19, designated BC-819, works to destroy cancerous cells only. BC-819 is in the clinical trial stage for treatment of ovarian cancer, pancreatic cancer and superficial bladder cancer. It has also been tested in compassionate use trials for liver cancer and kidney TCC. Clinical results have shown effectiveness in removing existing cancerous growths and keeping patients clear of new growths.

A clinical trial for ovarian cancer and a clinical trial for superficial bladder cancer are now accepting patients.